Purespring Therapeutics

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. Purespring Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $81.6 million. It has raised $165 million.

Last price · $/share
—
Implied valuation
$81.6M
Total raised
$164.7M
Last round
—
What is Purespring Therapeutics worth?
$81.6Mlast known valuation
Free account
More of Purespring Therapeutics with a free account
  • ·Watch Purespring Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Purespring Therapeutics funding history

No rounds on record

No funding rounds for Purespring Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Purespring Therapeutics valuation

Purespring Therapeutics's last known valuation is $81.6 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How Purespring Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Purespring Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Purespring Therapeutics

What is Purespring Therapeutics worth?
Purespring Therapeutics's last known valuation is $81.6M.
How much has Purespring Therapeutics raised?
Purespring Therapeutics has raised $164.7M in total funding across its recorded rounds.